These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 21853126)

  • 1. Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice.
    Yu R; Dhall D; Nissen NN; Zhou C; Ren SG
    PLoS One; 2011; 6(8):e23397. PubMed ID: 21853126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor.
    Zhou C; Dhall D; Nissen NN; Chen CR; Yu R
    Pancreas; 2009 Nov; 38(8):941-6. PubMed ID: 19657311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon receptor is required for long-term survival: a natural history study of the Mahvash disease in a murine model.
    Yu R; Ren SG; Mirocha J
    Endocrinol Nutr; 2012 Nov; 59(9):523-30. PubMed ID: 22951296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A natural inactivating mutant of human glucagon receptor exhibits multiple abnormalities in processing and signaling.
    Yu R; Wawrowsky K; Zhou C
    Endocrinol Nutr; 2011; 58(6):258-66. PubMed ID: 21680267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Serum Amino Acids Induce a Subpopulation of Alpha Cells to Initiate Pancreatic Neuroendocrine Tumor Formation.
    Smith DK; Kates L; Durinck S; Patel N; Stawiski EW; Kljavin N; Foreman O; Sipos B; Solloway MJ; Allan BB; Peterson AS
    Cell Rep Med; 2020 Aug; 1(5):100058. PubMed ID: 33205067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor.
    Longuet C; Robledo AM; Dean ED; Dai C; Ali S; McGuinness I; de Chavez V; Vuguin PM; Charron MJ; Powers AC; Drucker DJ
    Diabetes; 2013 Apr; 62(4):1196-205. PubMed ID: 23160527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia.
    Kedees MH; Grigoryan M; Guz Y; Teitelman G
    Mol Cell Endocrinol; 2009 Nov; 311(1-2):69-76. PubMed ID: 19647035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rescue of a pathogenic mutant human glucagon receptor by pharmacological chaperones.
    Yu R; Chen CR; Liu X; Kodra JT
    J Mol Endocrinol; 2012 Oct; 49(2):69-78. PubMed ID: 22693263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic α-cell hyperplasia: facts and myths.
    Yu R
    J Clin Endocrinol Metab; 2014 Mar; 99(3):748-56. PubMed ID: 24285676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations.
    Sipos B; Sperveslage J; Anlauf M; Hoffmeister M; Henopp T; Buch S; Hampe J; Weber A; Hammel P; Couvelard A; Höbling W; Lieb W; Boehm BO; Klöppel G
    J Clin Endocrinol Metab; 2015 May; 100(5):E783-8. PubMed ID: 25695890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of PNET formation and normal longevity in a mouse model of Mahvash disease.
    Xu Y; Liu Q; Chen CW; Wang Q; Du T; Yu R; Zhou Q; Yang D; Wang MW
    Heliyon; 2024 Aug; 10(15):e35362. PubMed ID: 39170309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors.
    Modali SD; Parekh VI; Kebebew E; Agarwal SK
    Mol Endocrinol; 2015 Feb; 29(2):224-37. PubMed ID: 25565142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon cell hyperplasia and neoplasia: a recently recognized endocrine receptor disease.
    Sipos B; Klöppel G
    Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37260318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice.
    Omar BA; Andersen B; Hald J; Raun K; Nishimura E; Ahrén B
    Diabetes; 2014 Jan; 63(1):101-10. PubMed ID: 24062250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of glucagon-like Peptide 1 receptor and its effects on biologic behavior in pancreatic neuroendocrine tumors.
    Cases AI; Ohtsuka T; Fujino M; Ideno N; Kozono S; Zhao M; Ohuchida K; Aishima S; Nomura M; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2014 Jan; 43(1):1-6. PubMed ID: 24326362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.
    Gelling RW; Du XQ; Dichmann DS; Romer J; Huang H; Cui L; Obici S; Tang B; Holst JJ; Fledelius C; Johansen PB; Rossetti L; Jelicks LA; Serup P; Nishimura E; Charron MJ
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1438-43. PubMed ID: 12552113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypercalcemia in Glucagon Cell Hyperplasia and Neoplasia (Mahvash Syndrome): A New Association.
    Gild ML; Tsang V; Samra J; Clifton-Bligh RJ; Tacon L; Gill AJ
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3119-3123. PubMed ID: 30032256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crispr-Cas9 mediated complete deletion of glucagon receptor in mice display hyperglucagonemia and α-cell hyperplasia.
    Yuan H; Kang Q; Li Z; Bai X; Jia J; Han D; Wu X; Li M
    Biochem Biophys Res Commun; 2023 Feb; 643():121-128. PubMed ID: 36596263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated clinicopathological features and gene microarray analysis of pancreatic neuroendocrine tumors.
    Zhou H; Chen Q; Tan W; Qiu Z; Li S; Song Y; Gao S
    Gene; 2017 Aug; 625():72-77. PubMed ID: 28479381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic pancreatic endocrine cell hyperplasia.
    Ouyang D; Dhall D; Yu R
    World J Gastroenterol; 2011 Jan; 17(2):137-43. PubMed ID: 21245985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.